Alnylam Pharmaceuticals
ALNY
#445
Rank
NZ$90.61 B
Marketcap
NZ$685.86
Share price
0.50%
Change (1 day)
59.25%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): NZ$0.31

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$0.15. In 2023 the company made an earnings per share (EPS) of NZ-$6.04 an increase over its 2022 EPS that were of NZ-$15.90.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$0.31
2023NZ-$6.04-62%
2022NZ-$15.9029.03%
2021NZ-$12.32-3.36%
2020NZ-$12.75-8.48%
2019NZ-$13.937.67%
2018NZ-$12.9439.74%
2017NZ-$9.2612.94%
2016NZ-$8.2038.84%
2015NZ-$5.91-32.88%
2014NZ-$8.80259.44%
2013NZ-$2.45-31.25%
2012NZ-$3.56

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
NZ-$2.14-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
NZ$74.36 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$4.69-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.41-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.25-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
NZ$12.60 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$6.34 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
NZ$1.08 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel